Cartherics and Catalent have strengthened their collaboration to accelerate the development and future commercialisation of advanced immune cell therapies.
At the centre of the partnership is an amended commercial license that allows Cartherics to use a Catalent induced pluripotent stem cell line manufactured under strict regulatory standards.
This cell line will serve as the foundation for producing Cartherics’ engineered natural killer cell therapies, including its lead candidate CTH 401. These therapies are designed to be available off the shelf, potentially improving accessibility and reducing costs compared to traditional personalised approaches.
Cartherics’ leadership views the agreement as a critical enabler of its long-term strategy. The company believes that working closely with Catalent will help streamline development and establish a reliable, scalable manufacturing pathway. This is expected to support both clinical progress and eventual commercial supply.
Catalent, for its part, sees the collaboration as an opportunity to contribute its expertise in cell therapy manufacturing to a program with meaningful clinical potential. Its teams are already engaged across multiple stages of development, helping ensure that processes are aligned from early research through to later stage production.
The licensed stem cell line is part of a broader portfolio developed under rigorous conditions, with fully validated methods covering every stage from cell reprogramming through to final quality control. This foundation has already delivered tangible progress, including regulatory clearance in the United States for the use of the cell line in the generation of Cartherics’ lead therapy. In addition, both companies have confirmed that the therapy integrates effectively with Catalent’s manufacturing platform.
Beyond immediate development goals, the agreement also establishes a flexible framework for future manufacturing. While Catalent is positioned to support late-stage trials and commercial production, Cartherics retains the ability to produce its own clinical materials and remain involved in downstream manufacturing as the partnership evolves.